Combination anti–CTLA-4 plus anti–PD-1 checkpoint blockade utilizes cellular mechanisms partially distinct from monotherapies

Immune checkpoint blockade therapy targets T cell-negative costimulatory molecules such as cytotoxic T lymphocyte antigen-4 (CTLA-4) and programmed cell death-1 (PD-1). Combination anti–CTLA-4 and anti–PD-1 blockade therapy has enhanced efficacy, but it remains unclear through what mechanisms such e...

Descripción completa

Detalles Bibliográficos
Autores principales: Wei, Spencer C., Anang, Nana-Ama A. S., Sharma, Roshan, Andrews, Miles C., Reuben, Alexandre, Levine, Jacob H., Cogdill, Alexandria P., Mancuso, James J., Wargo, Jennifer A., Pe’er, Dana, Allison, James P.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: National Academy of Sciences 2019
Materias:
Biological Sciences
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6842624/
https://www.ncbi.nlm.nih.gov/pubmed/31636208
http://dx.doi.org/10.1073/pnas.1821218116

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6842624/
https://www.ncbi.nlm.nih.gov/pubmed/31636208
http://dx.doi.org/10.1073/pnas.1821218116

Ejemplares similares